Phibro Animal Health (NASDAQ:PAHC) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.
Phibro Animal Health pays an annual dividend of $0.48 per share and has a dividend yield of 2.0%. Aprea Therapeutics does not pay a dividend. Phibro Animal Health pays out 31.4% of its earnings in the form of a dividend.
Insider & Institutional Ownership
49.3% of Phibro Animal Health shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Phibro Animal Health and Aprea Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Phibro Animal Health||$828.00 million||1.15||$54.71 million||$1.53||15.43|
Phibro Animal Health has higher revenue and earnings than Aprea Therapeutics.
This is a summary of current ratings and price targets for Phibro Animal Health and Aprea Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Phibro Animal Health||2||2||1||0||1.80|
Phibro Animal Health presently has a consensus price target of $26.60, indicating a potential upside of 12.66%. Aprea Therapeutics has a consensus price target of $26.33, indicating a potential upside of 2.99%. Given Phibro Animal Health’s higher probable upside, analysts plainly believe Phibro Animal Health is more favorable than Aprea Therapeutics.
This table compares Phibro Animal Health and Aprea Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Phibro Animal Health||4.99%||25.52%||7.34%|
Phibro Animal Health beats Aprea Therapeutics on 8 of the 10 factors compared between the two stocks.
Phibro Animal Health Company Profile
Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It also operates in Israel, Latin America, Canada, Europe, Africa, and the Asia/Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. The company is headquartered in Teaneck, New Jersey. Phibro Animal Health Corporation is a subsidiary of BFI Co., LLC.
Aprea Therapeutics Company Profile
Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company’s lead drug candidate APR-246, a small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies. It has commenced a Phase 3 clinical trial in p53 mutant MDS and completed enrollment in a Phase 1b/2 clinical trial in p53 mutant MDS and AML with APR-246 and azacitidine; and additional Phase 1/2 trials of APR-246 in MDS and AML in combination with approved anti-cancer therapies, as well as developing next generation p53 reactivators. The company was founded in 2003 and is based in Boston, Massachusetts.
Receive News & Ratings for Phibro Animal Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Phibro Animal Health and related companies with MarketBeat.com’s FREE daily email newsletter.